Athenex — Technical Presentation (March 2019)
10 slides from Athenex's technical presentation, Mar 4, 2019
Slide 1: KX2-391 Ointment 1% in Treatment of Actinic Keratosis in Two Pivotal Phase III Studies
KX2-391 Ointment 1%, a Novel Dual Src/Tubulin Inhibitor, in the Treatment of Adults with Actinic Keratosis in Two Pivotal Phase III Studies Edward Lain1, MD, Austin Institute for Clinical Research Inc, Pflugerville, TX (Presenter) Glynis Ablon1, MD, Ablon Skin Institute & Research Center, Manhattan
Slide 2: KX2-391 Mechanism of Action
KX2-391 Mechanism of Action Novel small molecule compound with differentiated mechanisms of actions: (1) inhibition of Src Kinase activity (2) inhibition of tubulin polymerization Upregulate apoptosis in proliferating cells KX2-391 Ointment 1% = KX2-391 free base + glyceryl monostearate + propylene
Slide 3: Two Identical Phase III Efficacy and Safety Studies of KX2-391 Ointment 1%
Two Identical Phase III Efficacy and Safety Studies of KX2-391 Ointment 1% in Adult Subjects with Actinic Keratosis (AK) (KX01-AK-003 and KX01-AK-004) Study Design: Double-blind, vehicle-controlled, randomized, parallel group, multicenter Treatment area: 25 cm2 with 4-8 typical visible AK lesions on
Slide 4: Demography and Baseline Characteristics - ITT Population
Demography and Baseline Characteristics - Intent-To-Treat (ITT) Population KX01-AK-003 N=351 KX01-AK-004 N=351 Number of Subjects (% of Subjects in ITT Population) KX2-391 N=175 Vehicle N=176 KX2-391 N=178 Vehicle N=173 Mean Age (years) 69.5 70.2 69.1 70.2 Gender: Male 147 (84%) 154 (88%) 158 (89%)
Slide 5: Efficacy Results of KX2-391 in Field Treatment of AK
Efficacy Results of KX2-391 in Field Treatment of AK - Intent-To-Treat (ITT) population Study KX01-AK-003 KX01-AK-004 % of Subjects in ITT Population (Number of Subjects) KX2-391 N=175 Vehicle N=176 p-value KX2-391 N=178 Vehicle N=173 p-value 100% AK Clearance 44% (N=77) 5% (N=8) <0.0001 54% (N=97)
Slide 6: Subgroup Analysis of 100% Clearance at Day 57
Subgroup Analysis of 100% Clearance at Day 57 - ITT Population Statistical significant difference in 100% clearance was demonstrated for all subgroups analyzed in both studies KX01-AK-003 KX01-AK-004 Subgroups KX2-391 Vehicle p-value KX2-391 Vehicle p-value Female Male 61% 41% 14% 3% 0.0007 <0.0001
Slide 7: Safety Results - Safety Population
Safety Results - Safety Population KX2-391 was well tolerated No ocular exposure that led to ocular AEs No related clinically significant abnormal EKGs, PEs, vital signs or laboratory findings Number of Subjects (% of Subjects in Safety Population) KX01-AK-003 N=351 KX01-AK-004 N=351 Number of subje
Slide 8: Local Skin Reactions (LSR) – Safety Population
Local Skin Reactions (LSR) – Safety Population 0-3 LSR grade: 0=absent; 1=mild (slightly or barely perceptible); 2=moderate (distinct presence); 3=severe (marked, intense); Composite LSR score is the sum of all 6 LSR (erythema, flaking/scaling, crusting, swelling, vesicles/pustules, erosions/ulcers)
Slide 9: Maximal Post-Baseline LSR at Grade 3 (Severe) - Safety Population
Maximal Post-Baseline LSR at Grade 3 (Severe) - Safety Population Number of Subjects (% of Subjects in Safety Population) KX01-AK-003 KX01-AK-004 KX2-391 N=175 Vehicle N=176 KX2-391 N=178 Vehicle N =173 Erythema 5 (3%) 0 17 (10%) 0 Flaking/Scaling 11 (6%) 0 20 (11%) 1 (<1%) Crusting 2 (1%) 0 5 (3%)
Slide 10: Conclusions
Conclusions KX2-391 ointment 1%, once daily for 5 days, resulted in higher overall complete AK clearance rates at Day 57 than Vehicle in two Phase III trials at 44% and 54%, respectively Statistical significant differences were demonstrated in all subgroups analyzed including for face and scalp Most